However, another cancer cell-centric mode of PD-L1 upregulation is considered as adaptive immune resistance [23], which is characterized by an increased expression of PD-L1 on tumor cells and immune cell subpopulation in reaction to robust CD8+ T-cell-mediated immunosurveillance. This evidence concerns the gene CD274 and cancer.